Latest news with #DrReddy
Economic Times
2 hours ago
- Business
- Economic Times
Stocks in news: Infosys, Bajaj Finance, Nestle, Dr Reddy's, Inox Wind
Markets traded with a positive bias and gained over half a percent, offering some relief after the recent decline. In today's trade, shares of Infosys, Bajaj Finance, Nestle, IndusInd Bank, Inox Wind among others will be in focus due to various news developments and first quarter results. ADVERTISEMENT Bajaj Finance, Nestle, SBI Life, Adani Energy, Canara Bank, Motilal, IEX Shares of Bajaj Finance, Nestle, SBI Life, Adani Energy, Canara Bank, Motilal and IEX will be in focus as the company will announce its first quarter results. Tata Consumer Tata Consumer reported a 15% growth in its Q1FY26 consolidated net profit at Rs 334 crore versus Rs 290 crore in the year ago period. Dr Reddy's Pharma major Dr Reddy's reported a marginal 2% year-on-year (YoY) growth in its consolidated net profit at Rs 1,418 crore for the first quarter ended June. Bajaj Housing Bajaj Housing Finance reported a 21% year-on-year jump in its net profit for the June quarter at Rs 583 crore. ADVERTISEMENT InfosysIndia's second largest IT services exporter Infosys reported 9% year-on-year (YoY) growth in its consolidated net profit at Rs 6,921 crore for the first quarter ended June. BEML BEML received order worth Rs 294 crore from the Ministry of Defence for the supply of HMV 6X6 ADVERTISEMENT Inox Wind Inox Wind said its board has approved the detailed terms of its proposed rights issue of equity shares aggregating up to Rs 1,249 crore, following in-principle approvals from BSE and NSE. IndusInd Bank IndusInd Bank will raise up to Rs 3000 crore ($3.47 billion). The Bank will issue debt worth Rs 2000 crore on a private placement basis and also increase capital by Rs 1000 crore through an additional issue or placement of securities. (You can now subscribe to our ETMarkets WhatsApp channel)
Time of India
11 hours ago
- Business
- Time of India
ET Market Watch: Markets rally on tariff relief; inside the 540-pt surge on D-Street
Transcript Hi, you're listening to ET Markets Radio. I am your host, Neha Vashishth. Welcome to a fresh episode of ET Market Watch -- where we bring you the latest news from the world of stock markets every single day. Let's get to it: Global trade diplomacy lifted markets today! Sensex jumped 540 points, Nifty closed above 25,200, thanks to a tariff-cutting deal between the US and Japan that boosted hopes around India-US trade talks. Global Rally Asian stocks surged, Japan's Nikkei soared 3.5%, MSCI Asia ex-Japan up 1.4%. Europe followed auto stocks zoomed, Stoxx 600 gained 1%. India Highlights Back home, HDFC Bank, ICICI Bank rallied for a third day. IT and financials led the gains. But realty tanked. Lodha and Oberoi Realty dropped sharply on block deals. Tata Consumer fell 2%, while Dr Reddy's inched up ahead of earnings. Technical Check Nifty's now above the 21-day EMA. RSI in bullish mode. Target? 25,500. Support? 24,900. Commodities & Currency Brent crude held at $68.47. Rupee steady, closing just shy of 86.50 vs dollar. Expert Take Analysts say optimism around India-UK FTA and easing global trade tensions could keep bulls in charge, at least for now.
Business Recorder
15 hours ago
- Business
- Business Recorder
Indian benchmarks shares track global rally on US-Japan trade deal boost
India's equity benchmarks rose on Wednesday, tracking other Asian markets as the United States' surprise trade deal announcement with Japan boosted hopes of agreements with other trading partners. The Nifty 50 rose 0.63% to 25,219.9 points and the BSE Sensex added 0.66% to 82,726.64. MSCI's broadest index for Asia-Pacific stocks outside Japan advanced 1.4%, while Japan's Nikkei 225 gained 3.5%. Stocks in Europe too surged as traders kept an eye on the EU-U.S. trade talks scheduled for later in the day. On the other hand, the prospects of an interim trade deal between India and the U.S. before Washington's August 1 deadline have dimmed, with talks deadlocked over tariff cuts on key agricultural and dairy products, Reuters reported, citing two Indian government sources. 'The gains in Indian market today have come on the back of a global rally. While there was anticipation of an interim deal between U.S. and India, it does not look like it will materialize before the August 1 deadline,' said VK Vijayakumar, chief investment strategist at Geojit Investments. Fifteen of the 16 major sectoral indexes logged gains. Heavyweights financials and information technology stocks rose 0.8% and 0.3%, respectively. India's stock benchmarks end flat as Reliance, trade jitters offset Eternal gains HDFC Bank and ICICI Bank rose 0.9% and 1%, respectively, marking their third day of gains after reporting upbeat earnings on Saturday. The broader small-caps ended flat, while mid-caps rose 0.3%. Real estate index fell 2.6%, with Lodha Developers and Oberoi Realty sliding 7.5% and 3.1%, respectively, following large block deals. Among other stocks, PNB Gilts surged 8.2% as its quarterly profit tripled on the back of gains made from securities. Tata Consumer Products slipped 2.1%, and Dr Reddy's Laboratories gained 0.6% ahead of their earnings.
Economic Times
15 hours ago
- Business
- Economic Times
Sensex settles 539 pts higher, Nifty tops 25,200 after US-Japan deal lifts sentiment
Live Events (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel Indian benchmark indices Sensex and Nifty closed higher on Wednesday, mirroring broad-based gains across Asian markets after a high-stakes trade pact between the United States and Japan stoked hopes of progress in India-US trade Sensex advanced 539.83 points, or 0.66%, to settle at 82,726.64, while the Nifty gained 159 points, or 0.63%, to close at 25, market capitalization of all listed companies on the BSE increased by Rs 82,186 crore to Rs 460.37 lakh the benchmark tracked a rally across Asian markets. MSCI's broadest index of Asia-Pacific shares outside Japan climbed 1.4%, while Japan's Nikkei 225 surged 3.5%, as investor sentiment improved ahead of a fresh round of EU-U.S. trade discussions later in the contrast, prospects for a limited trade deal between India and the U.S. ahead of Washington's August 1 deadline appeared to have faded, with talks reportedly stalled over tariff concessions on key agricultural and dairy products, according to Reuters, citing Indian government and information technology stocks added 0.8% and 0.3%, respectively, with HDFC Bank and ICICI Bank extending their post-earnings rally for a third straight session, rising 0.9% and 1%.Mid-cap stocks edged up 0.3%, while the broader small-cap segment was little estate lagged, with the sector index shedding 2.6% amid heavy selling in Lodha Developers and Oberoi Realty, which fell 7.5% and 3.1% following sizable block Consumer Products declined 2.1%, while Dr Reddy's Laboratories rose 0.6% ahead of quarterly Indian equity market demonstrated resilience despite a mixed start to Q1FY26 earnings and positive global cues, underpinned by optimism surrounding the U.S.-Japan trade agreement, have supported sentiment, said Vinod Nair, Head of Research, Geojit Investments."Additionally, progress toward finalising the India-UK FTA has further contributed to the constructive outlook. Continued advancements in global trade negotiations are expected to alleviate near-term trade tensions and foster greater market stability," said a technical basis, the Nifty has moved above the 21-day EMA on the daily timeframe, indicating an increase in bullish sentiment, supported by improved optimism following the trade deal between the U.S. and Japan, said Rupak De, Senior Technical Analyst at LKP Securities."The RSI on the daily chart is in a bullish crossover and rising above the 50 mark, further reinforcing the positive momentum. In the short term, sentiment is likely to remain optimistic. On the higher side, Nifty may move towards 25,500, while support is placed at 24,900. A break below this level could weaken the current trend," said equities rallied on Wednesday, underpinned by optimism over trade diplomacy after Japan struck a tariff-reducing agreement with the United States, lifting sentiment across major markets and sending Japanese shares to a one-year Nikkei 225 surged 3.5% following the announcement of a deal that lowers U.S. import duties on Japanese autos to 15%, averting a previously threatened 25% tariff that was set to take effect on August 1. While exclusions remain for certain goods such as steel and aluminium, the agreement marked a key step toward de-escalating trade Asia, Chinese blue-chip shares advanced 0.7% before paring gains, and MSCI's broadest index of Asia-Pacific stocks outside Japan added 1.2%.European markets followed suit, with the Euro Stoxx 600 rising 1% and auto stocks jumping 3.6%. UK equities climbed 0.5%, notching a fresh record Prime Minister Shigeru Ishiba said the U.S. had agreed not to impose volume caps on Japanese auto exports. U.S. President Donald Trump, posting on Truth Social, touted the pact as a win for American agriculture and industry, citing $550 billion in planned Japanese investments and improved access for U.S. rice, cars, and farm prices held near recent lows on Wednesday, stabilising after three straight sessions of declines, as a U.S.-Japan tariff agreement helped ease broader concerns over global trade crude slipped 12 cents, or 0.2%, to $68.47 a barrel by 0907 GMT, while U.S. West Texas Intermediate (WTI) fell 14 cents, also 0.2%, to $ Indian rupee ended marginally weaker on Wednesday, easing slightly from its previous close of 86.3675 but managing to stay above the critical 86.50 support level, supported by strength in the Chinese yuan and steady exporter dollar the U.S. dollar index, measuring the greenback against a basket of six major currencies, edged up 0.04% to 97.16.
Time of India
2 days ago
- Business
- Time of India
Dr Reddy's Q1 Results Preview: PAT may grow up to 15% YoY, revenue to surge up to 19%
Dr Reddy's Q1FY26 earnings are expected to show steady revenue growth and resilient domestic demand, with mixed profit estimates ranging from a 2% decline to 15% growth. US performance may be tempered by lower Revlimid sales, while domestic strength continues to support margins. Tired of too many ads? Remove Ads Here;s what brokerages recommended: Yes Securities Tired of too many ads? Remove Ads Phillip Capital Nuvama Kotak Equities Tired of too many ads? Remove Ads Dr Reddy's Laboratories is set to announce its Q1FY26 results on Wednesday, July 23. Brokerages project a mixed bag of earnings led by steady revenue growth, resilient domestic demand, and moderated US sales. Profit after tax (PAT) is seen in the range of Rs 1,399 crore to Rs 1,659 crore, reflecting a YoY growth between -2% and 15%. Revenue estimates hover between Rs 8,491 crore and Rs 9,094 crore, indicating a broad-based annual growth of 10–19%.The estimates of Yes Securitie, PhillipCapital, Nuvama Institutional Equities and Kotak Institutional Equities have been taken into Reddy's Q1 PAT is estimated at Rs 1,598 crore, reflecting a YoY growth of 14.8% and a marginal sequential (QoQ) uptick of 0.3%. The revenue for the quarter is pegged at Rs 8,616 crore, registering a 12% YoY increase and a 1% QoQ company's earnings before interest, tax, depreciation and amortisation (EBITDA) is expected to come in at Rs 2,229 crore. It is expected to go down by 181 bps YoY while rising by 154 bps sequentially."Revlimid trajectory would essentially determine US performance and we expect modest growth though still lower YoY as peak Revlimid sales might be behind. Gross margin had an element of one-off in Q4 to the extent of 300 bps which would reverse even as NRT consolidation implies margin would be below last year," this brokerage company's PAT is expected to grow 14% YoY and QoQ to Rs 1,659 crore in line with strong sales and operating performance. Revenue from operations may come in at Rs 9,094 crore, rising 19% YoY and 7% QoQ. Phillip Capital attributed this to the integration of Nicotinell acquisition, steady 8% growth in US sales supported by strong Revlimid (at $180 million vs $150 million last year), 11% growth in India and favorable is pegged at Rs 2,591 crore, likely up 19% YoY and a strong 21% QoQ while the EBITDA margin for the quarter could be reported at at 28.5%, expanding by 16 basis points on a YoY basis and a substantial 325 bps on a QoQ basis."Margins to remain stable at 28.5% as the price pressure in gRevlimid is compensated by favourable currency strong growth in Domestic formulation business, leading to a 19% YoY growth in EBITDA," this brokerage expects a PAT of Rs 1,399 crore in the quarter, marking a decline of 2% YoY and 12% QoQ. Revenue may stand at Rs 8,659 crore, registering a 13% increase YoY and a modest 2% rise may rise to Rs 2,255 crore, up 6% YoY and 6% QoQ."Revenue growth to be driven by growth in the India business. We expect gross/EBITDA margins to contract 340bp/130bp YoY to 57%/26.4%. We build EBITDA/PAT growth to be 8%/-1% YoY," this brokerage Equities, in its Q1FY26 preview, expects the company to report a PAT of 1,477 crore, marking a growth of 6.1% YoY and 7.3% QoQ. Net sales are projected at Rs 8,491 crore, rising 10.3% YoY but showing a slight sequential dip of 0.4%.EBITDA is estimated at Rs 2,105 crore, reflecting a marginal decline of 1.2% YoY but an increase of 1.5% QoQ. Meanwhile, the EBITDA margin is seen at 24.8%, contracting by 289 basis points YoY but improving by 46 basis points sequentially.
